GB9725764D0 - HLA-E binding - Google Patents

HLA-E binding

Info

Publication number
GB9725764D0
GB9725764D0 GBGB9725764.6A GB9725764A GB9725764D0 GB 9725764 D0 GB9725764 D0 GB 9725764D0 GB 9725764 A GB9725764 A GB 9725764A GB 9725764 D0 GB9725764 D0 GB 9725764D0
Authority
GB
United Kingdom
Prior art keywords
cells
hla
binding
nkg2
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9725764.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB9725764.6A priority Critical patent/GB9725764D0/en
Publication of GB9725764D0 publication Critical patent/GB9725764D0/en
Priority to AT98959027T priority patent/ATE438096T1/de
Priority to JP2000523554A priority patent/JP4336451B2/ja
Priority to EP09165917A priority patent/EP2144065A1/en
Priority to US09/555,555 priority patent/US7410767B1/en
Priority to EP98959027A priority patent/EP1036327B1/en
Priority to DE69841020T priority patent/DE69841020D1/de
Priority to PCT/GB1998/003686 priority patent/WO1999028748A2/en
Priority to US12/109,990 priority patent/US20080274475A1/en
Priority to JP2008314107A priority patent/JP4437160B2/ja
Priority to JP2009191564A priority patent/JP5268828B2/ja
Priority to JP2013006244A priority patent/JP2013081478A/ja
Priority to US14/683,835 priority patent/US20150361180A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
GBGB9725764.6A 1997-12-04 1997-12-04 HLA-E binding Ceased GB9725764D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding
PCT/GB1998/003686 WO1999028748A2 (en) 1997-12-04 1998-12-04 Hla-e binding
DE69841020T DE69841020D1 (de) 1997-12-04 1998-12-04 HLA-E Bindung zu CD94/NKG2+ Zellen
JP2000523554A JP4336451B2 (ja) 1997-12-04 1998-12-04 Ｈｌａ−ｅ結合
EP09165917A EP2144065A1 (en) 1997-12-04 1998-12-04 HLA-E Binding
US09/555,555 US7410767B1 (en) 1997-12-04 1998-12-04 HLA-E binding
EP98959027A EP1036327B1 (en) 1997-12-04 1998-12-04 HLA-E binding to CD94/NKG2+ cells
AT98959027T ATE438096T1 (de) 1997-12-04 1998-12-04 Hla-e bindung zu cd94/nkg2+ zellen
US12/109,990 US20080274475A1 (en) 1997-12-04 2008-04-25 Hla-e binding
JP2008314107A JP4437160B2 (ja) 1997-12-04 2008-12-10 Ｈｌａ−ｅ結合
JP2009191564A JP5268828B2 (ja) 1997-12-04 2009-08-21 Ｈｌａ−ｅ結合
JP2013006244A JP2013081478A (ja) 1997-12-04 2013-01-17 Ｈｌａ−ｅ結合
US14/683,835 US20150361180A1 (en) 1997-12-04 2015-04-10 Hla-e binding

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9725764.6A GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding

Publications (1)

Publication Number Publication Date
GB9725764D0 true GB9725764D0 (en) 1998-02-04

Family

ID=10823165

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9725764.6A Ceased GB9725764D0 (en) 1997-12-04 1997-12-04 HLA-E binding

Country Status (7)

Country Link
US (3) US7410767B1 (enExample)
EP (2) EP1036327B1 (enExample)
JP (4) JP4336451B2 (enExample)
AT (1) ATE438096T1 (enExample)
DE (1) DE69841020D1 (enExample)
GB (1) GB9725764D0 (enExample)
WO (1) WO1999028748A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
EP1423140A2 (en) * 2001-07-31 2004-06-02 Karl Petter Söderström Compositions and methods for modulation of immune responses
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP1664110B1 (en) * 2003-08-26 2008-08-20 Danmarks Tekniske Universitet A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
EP1781313A4 (en) 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
EP1831258B2 (en) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
ES2871349T3 (es) 2012-09-04 2021-10-28 Inven2 As Expansión selectiva y controlada de células NK educadas
AU2014248605B2 (en) * 2013-03-12 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for modification of HLA
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US20170081411A1 (en) * 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2015148960A1 (en) * 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
EP3193931B1 (en) 2014-09-16 2020-08-05 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
AU2015316993B2 (en) 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
KR102598068B1 (ko) 2014-10-23 2023-11-06 이나뜨 파르마 에스.에이. 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
SI3405495T1 (sl) 2016-01-21 2021-08-31 Innate Pharma Nevtralizacija inhibitornih poti v limfocitih
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN111801348A (zh) * 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
CN112351795A (zh) * 2018-02-23 2021-02-09 安贝科思生物制剂公司 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
SG11202105480WA (en) * 2018-12-02 2021-06-29 Fate Therapeutics Inc IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
CA3197662A1 (en) 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
EP4388012A4 (en) * 2021-08-20 2025-09-17 Univ Duke ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES
WO2024036303A2 (en) * 2022-08-11 2024-02-15 The Trustees Of The University Of Pennsylvania Universal t cells and compositions and methods of use thereof
EP4688859A1 (en) * 2023-03-24 2026-02-11 Duke University Antibodies that target hla-e-host peptide complexes and uses thereof
WO2026016730A1 (zh) * 2024-07-17 2026-01-22 广州瑞风生物科技股份有限公司 一种突变hla-e重链、hla-e三聚体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding

Also Published As

Publication number Publication date
JP2013081478A (ja) 2013-05-09
JP2010024233A (ja) 2010-02-04
JP2009106299A (ja) 2009-05-21
JP5268828B2 (ja) 2013-08-21
US7410767B1 (en) 2008-08-12
WO1999028748A3 (en) 1999-12-23
WO1999028748A2 (en) 1999-06-10
EP1036327A2 (en) 2000-09-20
US20150361180A1 (en) 2015-12-17
JP4437160B2 (ja) 2010-03-24
DE69841020D1 (de) 2009-09-10
JP2002513541A (ja) 2002-05-14
US20080274475A1 (en) 2008-11-06
EP2144065A1 (en) 2010-01-13
EP1036327B1 (en) 2009-07-29
JP4336451B2 (ja) 2009-09-30
ATE438096T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
WO1999028748A3 (en) Hla-e binding
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
ATE14021T1 (de) Verwendung von in wasser dispergierbaren polyisocyanat-zubereitungen als zusatzmittel fuer waessrige klebstoffe.
NZ333128A (en) Engineered human DNase I with DNA hydrolytic activity at least 50 percent greater than native human DNase I
HUT68261A (en) Synthetic dna sequence having enhanced insecticidal activity in maize
AU3166993A (en) Insulators for use in railway rail-fastening assemblies
WO1988002763A3 (en) Nucleating system for polyamides
ATE425985T1 (de) Verfahren zur markierung von rns
EA199900475A1 (ru) Получение растительных гелей
IL113315A (en) Insecticidal fertilizer mixtures
ES2157164B1 (es) Un aparato,un procedimiento y un sistema para recibir informacion,un aparato para enviar informacion a un terminal de informacion portatil,un procedimiento de envio de informacion desde un aparato a un terminal de informacion portatil y un sistema para enviar y recibir informacio
PL343841A1 (en) Substance system
EA199800867A1 (ru) Соединения тетрагидробетакарболина
AU1799188A (en) Anti-oxidant products
GR3032393T3 (en) Deoxygenation of an oil product with a laccase
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
GR3033942T3 (en) Method of identifying substances with a potential herbicidal or growth-regulatory action by means of vegetable transporter proteins, use of such transporter proteins for this purpose, and substances with a herbicidal or growth-regulatory action identified by the method
MY106240A (en) Novel strains of bacillus thuringiensis, methods for the preparation thereof and use thereof controlling insecis and protecting plants from insects attack
AU6505898A (en) Sperm extender comprising native phosphocaseinate or beta-lactoglobulin, method for preparing same and uses
GB9416536D0 (en) Orphan receptor
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.
AU2958292A (en) Method and device for harvesting useful plants
HU9602129D0 (en) Condensation and addition polymers with n,n'-bridged bis-tetramethylpiperidinyloxy groups
AU1720497A (en) Use of primers for universal fingerprint analysis
WO2000027873A3 (en) Interleukin-2 binding protein from arthropods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)